DR-0202 for Advanced Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores the safety and activity of a new treatment, DR-0202, for advanced cancers that have returned or do not respond to other treatments. Participants will receive varying doses of DR-0202 every two weeks to determine the most effective dose. The trial seeks individuals with specific types of advanced cancer, such as breast, lung, or ovarian cancer, who have tried at least two other treatments without success. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Do I need to stop my current medications to join the trial?
You may need to stop certain medications before joining the trial. There is a required 'washout period' (time without taking certain medications) for systemic chemotherapy and anticancer therapies, which is 4 weeks or 5 half-lives of the drug, whichever is shorter. However, low-dose corticosteroids and some other medications are allowed, so it's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that DR-0202 is likely to be safe for humans?
Research has shown that DR-0202 is a new treatment being tested for safety in people with advanced cancer. This phase 1 trial aims to determine if DR-0202 is safe for humans and to find the right dose.
Specific data on how patients handle DR-0202 is not yet available, but early trials like this typically focus on identifying any side effects. As this is the first step in human testing, researchers are still gathering safety information. The treatment might have side effects, but researchers closely monitor participants to ensure their safety.
If a treatment has been used safely in other trials or is approved for other conditions, it can provide some confidence in its safety. However, DR-0202 remains under study, so new information will emerge as the study progresses.12345Why do researchers think this study treatment might be promising for cancer?
DR-0202 is unique because it offers a range of dosage levels, allowing researchers to fine-tune its effectiveness and safety for advanced cancer patients. Unlike traditional chemotherapy, which often targets all rapidly dividing cells, DR-0202 is designed to be more selective, potentially reducing side effects. Researchers are excited about this treatment because it may provide a more personalized approach to cancer therapy, giving patients tailored dosages to maximize benefits while minimizing risks.
What evidence suggests that this trial's treatment, DR-0202, could be effective for advanced cancer?
Research has shown that DR-0202 is a new treatment called a bispecific antibody, which targets two different proteins simultaneously. This method may enhance the immune system's ability to attack cancer cells. In some lab studies, DR-0202 slowed the growth of certain cancer cells. Although human studies provide limited information, these early results suggest that DR-0202 might help treat advanced cancers unresponsive to other treatments. More research is needed to confirm these initial findings. Participants in this trial will receive different dosages of DR-0202 to evaluate its effectiveness and safety.12567
Who Is on the Research Team?
Wan Jen Hong, MD
Principal Investigator
Dren Bio
Are You a Good Fit for This Trial?
This trial is for adults with various advanced or metastatic cancers that have come back or didn't respond to treatment. Specific types include breast, endometrial, bladder, gastroesophageal junction, thyroid, lung (non-small cell), squamous cell carcinoma of the head and neck region including throat cancer, cervical, ovarian, stomach, prostate and pancreatic cancers.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation/Expansion
Participants receive varying doses of DR-0202 every 2 weeks until progression or withdrawal
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- DR-0202
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dren Bio
Lead Sponsor